HOME › DRUGS › ERIBULIN
ACTIVE SUBSTANCE / INN

ERIBULIN

Brand name(s): Mevlyq, Halaven, Eribulin Baxter
EMA LISTED
AUTHORISED
Breast Neoplasms;Liposarcoma
ACTIVE SUBSTANCE
Eribulin
REGULATORS
EMA
SPONSORS / MAH
Eisai GmbH, YES Pharmaceutical Development Services GmbH, Baxter Holding B.V.
TOTAL APPLICATIONS
3
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Eribulin BaxterBaxter Holding B.V.Authorised27/06/2024Breast Neoplasms;Liposarcoma
MevlyqYES Pharmaceutical Development Services GmbHAuthorised09/02/2024Breast Neoplasms;Liposarcoma
HalavenEisai GmbHAuthorised17/03/2011Breast Neoplasms;Liposarcoma

FULL INTELLIGENCE ON ERIBULIN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →